AndroGel Liver Function Impact: What the Clinical Evidence Shows

Why the Route of Administration Determines Liver Risk

Transdermal testosterone gel does not require passage through the portal circulation before reaching systemic blood. This single pharmacokinetic fact separates AndroGel from oral testosterone undecanoate capsules and, far more importantly, from 17-alpha-alkylated oral androgens such as methyltestosterone and oxymethalone, which resist hepatic degradation and accumulate in hepatocytes.

The FDA prescribing information for AndroGel 1.62% notes that the hepatic effects observed with oral androgens, including peliosis hepatis, hepatocellular carcinoma, and cholestatic jaundice, are not established findings with transdermal formulations. [1] That distinction is not trivial for clinicians choosing a testosterone-replacement route in men with pre-existing metabolic liver disease or elevated baseline transaminases.

First-Pass Metabolism: A Pharmacokinetic Primer

After topical application, testosterone is absorbed through the stratum corneum and enters the peripheral circulation directly. Plasma testosterone rises over approximately two to four hours post-application, reaching steady-state within 24-48 hours of daily dosing. [2] Hepatic first-pass extraction, which can exceed 90% for oral steroidal compounds, is essentially eliminated.

17-alpha-alkylated oral androgens survive first-pass because the chemical modification at C-17 blocks hepatic oxidation. That same modification is what generates the reactive metabolites responsible for cholestasis, canalicular damage, and, in prolonged high-dose use, peliosis hepatis and hepatocellular adenoma. AndroGel contains unmodified testosterone. Hepatic enzymes degrade it normally. [3]

What "Normal Hepatic Metabolism" Means for Enzyme Levels

Testosterone metabolized in the liver primarily yields androstenedione, dihydrotestosterone precursors, and glucuronide or sulfate conjugates excreted in bile and urine. This metabolic pathway does not generate hepatotoxic intermediates under standard replacement doses. ALT and AST elevations attributable directly to transdermal testosterone are uncommon and generally mild when they do occur. [4]

A clinically relevant nuance: elevated ALT in men on TRT is sometimes due to increased muscle turnover rather than hepatocellular injury. Serum ALT is present in both hepatocytes and skeletal muscle. Concurrent resistance training or a rise in lean mass during testosterone replacement may raise ALT 10-20% above baseline without any hepatic pathology. Checking AST/ALT ratio and gamma-glutamyl transferase (GGT) together helps differentiate the two sources. [5]

Evidence From the T-Trials

The Testosterone Trials (T-Trials) represent the most rigorous placebo-controlled evaluation of testosterone therapy in older men to date. The coordinated set of seven trials enrolled 788 men aged 65 years or older with confirmed hypogonadism (average morning testosterone <275 ng/dL on two measurements) and randomized them to testosterone gel 1% titrated to maintain levels between 500 and 900 ng/dL or placebo gel for 12 months. [6]

Liver-Related Findings in the T-Trials

Liver enzyme data were collected as part of the safety monitoring protocol across the T-Trials. The published primary results reported no excess of serious hepatic adverse events in the testosterone arm versus placebo over 12 months of daily gel application. [6] The Sexual Function Trial component, published in the New England Journal of Medicine in 2016, listed adverse events systematically, and clinically significant ALT or AST elevations requiring treatment discontinuation were not identified as a distinguishing safety signal. [6]

This finding is consistent with the broader mechanistic expectation: 788 older men, many with metabolic syndrome and baseline hepatic steatosis, tolerated 12 months of transdermal testosterone without generating a hepatic safety signal distinct from placebo. That does not mean liver monitoring is unnecessary; it means the risk profile is qualitatively different from oral androgen therapy.

Hematocrit and Cardiovascular Safety Context

The T-Trials did identify an increase in cardiovascular events in the testosterone group (23 vs. 5 major adverse cardiovascular events in the cardiovascular trial component), which led the FDA to review TRT labeling. [7] Subsequent labeling changes focused on cardiovascular risk, not hepatic risk, for transdermal formulations. Clinicians should keep both risk domains in view during long-term follow-up.

Comparing Hepatic Risk Across Testosterone Formulations

Not all testosterone-replacement options carry the same liver profile. Understanding the hierarchy guides prescribing decisions when a patient has pre-existing liver disease or persistently elevated baseline transaminases.

Oral 17-Alpha-Alkylated Androgens

Methyltestosterone and stanozolol, still occasionally encountered in older formularies and compounded preparations, carry well-documented hepatotoxicity. Cholestatic jaundice, peliosis hepatis, and hepatocellular carcinoma have all been linked to these agents in peer-reviewed literature. The American Association for the Study of Liver Diseases (AASLD) includes 17-alpha-alkylated androgens as recognized causes of drug-induced liver injury. [8]

Oral Testosterone Undecanoate (Jatenzo, Tlando)

Modern oral testosterone undecanoate formulations use a lipid-based delivery system that routes absorption through intestinal lymphatics, partially bypassing portal first-pass. Hepatic enzyme elevations are less frequent than with alkylated androgens but still more common than with transdermal gel, and FDA labeling for Jatenzo carries a warning regarding blood pressure elevation that has partially shifted prescriber attention from hepatic to cardiovascular concerns. [9]

Injectable Testosterone Esters

Testosterone cypionate and enanthate administered intramuscularly also bypass first-pass metabolism. Their hepatic safety profile is broadly comparable to transdermal gel, though supraphysiologic peaks in the days immediately after injection may transiently stress hepatic clearance pathways more than the steady-state delivery of daily gel. Evidence for clinically meaningful liver injury from standard-dose injectable esters at therapeutic dosing intervals is limited. [10]

Transdermal Gel: The Hepatic Favorable Option

Among available testosterone-replacement formulations, transdermal gel and transdermal patches represent the lowest hepatic-risk category. The steady-state delivery, absence of 17-alpha-alkylation, and avoidance of portal first-pass combine to produce a pharmacokinetic profile that does not stress hepatocyte detoxification capacity at approved doses. [2]

Baseline Assessment and Monitoring Protocol

Even with a favorable hepatic profile, a structured monitoring approach is appropriate for any man starting AndroGel, both to detect the rare individual who develops enzyme elevation and to capture pre-existing liver disease that could alter management.

Before Starting AndroGel

Obtain a comprehensive metabolic panel (CMP) that includes ALT, AST, alkaline phosphatase (ALP), total bilirubin, and albumin. Document baseline values explicitly because testosterone therapy can increase lean body mass and exercise capacity, secondarily raising ALT from muscle, and having a true pre-treatment baseline prevents misattribution.

Screen for heavy alcohol use. Alcohol-related hepatic steatosis and fibrosis are common in the age groups most often prescribed TRT. A patient with Child-Pugh B or C cirrhosis requires specialist involvement before initiating any androgen therapy.

Review the medication list for drugs with additive hepatic burden: statins, azole antifungals, amiodarone, and methotrexate are common co-prescriptions in hypogonadal men aged 50 and older.

During Therapy: Monitoring Intervals

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends checking serum testosterone, hematocrit, PSA, and a lipid panel at 3-6 months after initiation and then annually. [11] Liver function tests are not assigned a mandatory interval in that guideline for transdermal formulations, reflecting the low intrinsic hepatic risk. Most clinicians include LFTs at the 3-to-6-month check and then annually as part of the CMP.

The 2023 American Urological Association (AUA) guideline on testosterone deficiency similarly notes that routine hepatic monitoring is recommended, with frequency left to physician discretion for transdermal testosterone. [12] Persistent ALT elevations above three times the upper limit of normal (ULN) should prompt suspension of therapy and hepatology referral.

Interpreting an Elevated ALT on Therapy

An ALT that rises modestly (1.0-1.5 times ULN) after starting AndroGel warrants a structured differential rather than automatic discontinuation. Check:

• GGT: elevated GGT with normal ALP suggests alcohol or drug-related hepatic stress rather than muscle-origin ALT.
• AST/ALT ratio: a ratio above 2:1 in the setting of heavy drinking is characteristic of alcoholic hepatitis; a ratio below 1:1 is more consistent with non-alcoholic steatohepatitis or skeletal muscle elevation.
• Creatine kinase (CK): a concurrent CK elevation confirms muscle as the ALT source when testosterone is increasing lean mass.
• Right upper quadrant ultrasound: appropriate if ALT exceeds 1.5 times ULN for more than 6 weeks or if clinical signs of hepatic disease appear.

Special Populations: Pre-Existing Liver Disease

Men with non-alcoholic fatty liver disease (NAFLD) represent a large and growing portion of the hypogonadal population. The relationship is bidirectional: low testosterone independently associates with hepatic steatosis and fibrosis progression, and NAFLD associates with suppression of the hypothalamic-pituitary-gonadal axis. [13]

NAFLD and TRT

Small prospective studies suggest that restoring testosterone to the normal range may reduce hepatic fat fraction in hypogonadal men with NAFLD, possibly through improvements in insulin sensitivity and visceral adiposity reduction. A 2019 study published in the European Journal of Endocrinology (N=184 hypogonadal men with type 2 diabetes, using testosterone undecanoate) showed statistically significant reductions in liver enzymes at 24 and 42 months versus controls, with ALT falling from a mean of 38 U/L to 29 U/L at 42 months (P<0.05). [14] Transdermal gel has not been studied in an equivalent dedicated NAFLD trial of that duration, but the mechanistic pathway, improved insulin sensitivity and visceral fat reduction, applies across formulations.

Cirrhosis

Established cirrhosis (Child-Pugh B or C) is a relative to absolute contraindication for testosterone therapy. Reduced hepatic synthetic function, portal hypertension, and impaired androgen metabolism all complicate management. The Endocrine Society guideline explicitly recommends against initiating testosterone therapy in men with severe liver disease until the hepatic condition is addressed. [11]

Child-Pugh A cirrhosis with compensated function requires a careful individual benefit-risk discussion. If therapy proceeds, transdermal gel is preferable over oral options, and LFTs should be checked monthly for the first three months.

What the FDA Label Actually States About Liver

The current FDA prescribing information for AndroGel 1.62% lists the following under warnings and precautions regarding hepatic effects: peliosis hepatis and hepatocellular carcinoma have been associated with prolonged high-dose androgen therapy; these conditions are seen with oral anabolic steroids and are not a recognized complication of topical testosterone gel at therapeutic doses. [1]

The label does retain a general caution to monitor liver function in patients with pre-existing hepatic conditions and to discontinue therapy if evidence of hepatic dysfunction emerges. No boxed warning specific to hepatic injury exists for transdermal testosterone gel formulations as of the most recent label revision reviewed for this article. [1]

The FDA also notes that AndroGel is contraindicated in men with known or suspected carcinoma of the prostate or breast, and that patients with serious cardiac, hepatic, or renal disease may retain sodium and fluid. Edema with or without congestive heart failure may be a complication in patients with pre-existing hepatic compromise and hypoalbuminemia. [1]

Drug Interactions That Affect Hepatic Enzyme Readings

Several medications frequently co-prescribed with AndroGel can independently alter liver enzyme readings, complicating attribution during monitoring.

Corticosteroids used concurrently may raise alkaline phosphatase through bone isoenzyme induction. Statins, taken by a substantial proportion of men receiving TRT for cardiovascular risk management, cause transaminase elevations in roughly 1-3% of patients at standard doses. [15] Azole antifungals (ketoconazole, itraconazole) inhibit CYP3A4 and may increase testosterone plasma concentrations by reducing hepatic clearance, potentially amplifying any minor hepatic burden. [1]

Warfarin interacts pharmacodynamically with testosterone: androgen therapy may increase the anticoagulant effect of warfarin, requiring closer INR monitoring. This interaction is not a hepatic toxicity mechanism but is relevant to the overall monitoring visit when liver function is also assessed. [1]

Practical Prescribing Notes for Clinicians

Starting dose for AndroGel 1.62% is 40.5 mg (two pump actuations or two packets) applied to the shoulders or upper arms once daily. Dose adjustment based on morning serum testosterone measured 14 days after initiation or last dose change. Target range is 400-700 ng/dL for most men, though the T-Trials titrated to 500-900 ng/dL. [6]

For men with ALT between 1.5 and 3 times ULN at baseline due to NAFLD or metabolic syndrome, the risk-benefit of transdermal testosterone therapy is generally favorable given the hepatic-protective metabolic effects observed in observational data. Formal hepatology clearance is prudent before initiation.

Men with ALT above 3 times ULN at baseline should not begin AndroGel until the elevation is evaluated and a cause identified. If the elevation is attributable entirely to NAFLD with biopsy-confirmed NASH and no bridging fibrosis, and the hepatologist agrees, transdermal testosterone may be considered with monthly LFT monitoring for the first six months.